Targeting IL-23 for Therapeutic Longevity in Psoriasis
Activity Components
An Introduction to the Immunopathogenesis of Psoriasis and Rationale for Targeted Biologics: Why Target IL-23?
Key Cytokines Involved in Psoriasis Pathogenesis
Consequences of IL-23 Specific Inhibition
IL-23 as a Master Switch in Psoriasis
Summary
IL-23 Inhibitors for Biologic-Naive Psoriasis Patients
IL-23 Inhibitors in Moderate to Severe Psoriasis -- Approved and in Latest Development Stages
Guselkumab vs Adalimumab: VOYAGE-1 and VOYAGE-2
Guselkumab vs Secukinumab: ECLIPSE
Tildrakizumab vs Etanercept: reSURFACE-1 and reSURFACE-2
Risankizumab vs Ustekinumab -- ultIMMA and Risankizumab vs Adalimumab -- IMMvent
Mirikizumab: PASI 90 at Week 16 Phase 2 Study
Ranking of IL-23p19 Inhibitors -- Expert Perspective
IL-23p19 Inhibitors -- Insights on Remission and Disease-Modifying Effect
Summary
IL-23 Inhibitors for Biologic-Experienced Psoriasis Patients
Advantages of IL-23p19 Inhibitors
IL-23 Inhibitors in PsA
Advantages of IL-23p19 Inhibitors (cont)
Safety: IL-17 and IL-23p19 Inhibitors
Summary
IL-23 Inhibitors: Where They Fit in the Treatment Paradigm and Their Impact on Clinical Practice
Patient-Based Approach to Care
Secukinumab After Anti-TNF-α Failure
Long-Term Responses From Guselkumab vs Secukinumab in the ECLIPSE Trial
Patient-Specific Factors When Choosing IL-23 Antagonist Therapy
Summary
Abbreviations